Credit Assessment: COZART LIMITED

1. Credit Opinion: APPROVE

Reasoning: COZART LIMITED benefits from being a wholly-owned subsidiary of Abbott Toxicology Limited (owning >75% of shares), which itself is part of the Abbott Group — a global healthcare conglomerate. This parentage provides significant implicit financial backing, operational support, and brand credibility. The company has maintained an active status for over 20 years since incorporation in 2004, demonstrates good compliance discipline with no overdue filings, and carries substantial share capital of approximately £1.15M. The transition from PLC to Limited in 2007 aligns with a typical acquisition restructure, and the continued operation under Abbott ownership suggests strategic value within the group. On a standalone basis, the small filing category limits visibility into detailed financials, but the structural support from Abbott materially mitigates standalone credit concerns.

2. Financial Strength

Positive Indicators: - Share capital of £1,152,964 signals meaningful capitalisation and long-term investment in the business - 20+ year operating history (incorporated 2004) demonstrates business longevity and survival through multiple economic cycles - No liquidation or adverse status flags — company remains Active with clean registry standing

Limitations: - Small company filing category means abbreviated accounts only; full P&L, detailed balance sheet, and cash flow statements are not publicly available - Net assets, profitability metrics, and leverage ratios cannot be independently verified from filed data - Reliance on parent company financial strength as the primary credit support

Group Support Assessment: Abbott Toxicology Limited's >75% ownership provides: - Likely intercompany financial support mechanisms (loans, guarantees, trade credit backstops) - Access to group procurement, distribution, and R&D infrastructure - Implicit "too important to fail" dynamic if COZART serves a strategic role in Abbott's toxicology portfolio

3. Cash Flow Assessment

Available Evidence: - Filing compliance is strong — accounts made up to 31 December 2025, next due 30 September 2027, with no overdue status on either accounts or confirmation statements - Continued operation over two decades suggests sustainable cash generation capacity - Substantial share capital indicates the business has been equity-funded rather than over-leveraged

Constraints: - Without filed P&L or cash flow data, debt service coverage, operating cash flow, and working capital metrics cannot be calculated - Intercompany transaction volumes with Abbott group entities are unknown — these could significantly impact standalone liquidity - No visible charges or security registrations noted, suggesting limited third-party debt, but this requires confirmation via a full registry search

Working Capital Consideration: As a manufacturer (SIC 32500 — medical/dental instruments), the business likely carries inventory and trade debtors typical of the sector. Parent company backing likely provides favourable payment terms with group suppliers.

4. Monitoring Points

Sector Context: Medical device/instrument manufacturing carries moderate cyclicality but benefits from structural demand drivers. Toxicology is a specialist niche with regulatory barriers to entry, supporting margin resilience.